Department of Orthopedic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Orthopedics Research Institute, Zhejiang University, Hangzhou, China.
J Biomed Mater Res B Appl Biomater. 2020 Feb;108(2):377-390. doi: 10.1002/jbm.b.34396. Epub 2019 Apr 29.
Application of bioactive materials as synthetic bone graft substitutes in regenerative medicine has seen great evolution over the past decades in treating challengeable bone defects. However, balancing the preparation conditions and biological performances of inorganic biomaterials remain a great challenge, especially when there is lack of biomaterial design on how to control component distribution and how pathological bone responds to the biomaterial stimulations and osteogenesis. Here, our objective is to develop yolk-shell Ca-silicate microspheres and to investigate the potential biological performances to overcome the limitations in repair of osteoporotic bone defects. The introduction of β-calcium silicate (CaSiO ) or mesoporous bioactive glass (MBG) into self-curing β-dicalcium silicate (Ca SiO ) cement shell to form spherical granules (CaSiO @Ca SiO , MBG@Ca SiO ) was to retain the physicochemical property and/or microstructure of each component for optimizing bioactive ion release that could maximize osteostimulation in osteoporosis. We report a scalable shape-controlled mild fabrication protocol to yield the yolk-shell granules, endowing to different phases in yolk layer and interconnected macropore networks in the closely packed granule scaffolds. This unique heterostructure preparation is governed by coaxially aligned bilayer nozzle, inorganic powders and biocompatible binders. Extensive in vitro and in vivo evaluation showed that the CaSiO @Ca SiO and MBG@Ca SiO granules exhibited many superior properties such as controllable ion release, improved biodegradation and enhanced osteogenic capability in comparison with the pure Ca SiO @Ca SiO , thereby opening new mild-condition approach in fabricating osteogenesis-tailored silicate biomaterials for bone regenerative medicine, especially for efficient reconstruction of challenging pathological bone defects.
生物活性材料在再生医学中作为合成骨移植物替代品的应用在过去几十年中取得了重大进展,可用于治疗具有挑战性的骨缺损。然而,平衡无机生物材料的制备条件和生物学性能仍然是一个巨大的挑战,特别是当缺乏关于如何控制成分分布以及病理性骨骼如何响应生物材料刺激和成骨的生物材料设计时。在这里,我们的目标是开发蛋黄壳硅酸钙微球,并研究其潜在的生物学性能,以克服骨质疏松性骨缺损修复的局限性。将β-硅酸钙(CaSiO )或介孔生物活性玻璃(MBG)引入自固化β-二硅酸钙(CaSiO )水泥壳中形成球形颗粒(CaSiO @CaSiO ,MBG@CaSiO ),目的是保留各组分的物理化学性质和/或微观结构,优化生物活性离子的释放,从而最大限度地提高骨质疏松症中的成骨刺激作用。我们报告了一种可扩展的形状可控温和制造方案,以产生蛋黄壳颗粒,赋予蛋黄层不同的相和紧密堆积颗粒支架中的相互连通的大孔网络。这种独特的异质结构制备受同轴双喷嘴、无机粉末和生物相容性粘结剂控制。广泛的体外和体内评价表明,与纯 CaSiO @CaSiO 相比,CaSiO @CaSiO 和 MBG@CaSiO 颗粒表现出许多优异的性能,如可控的离子释放、改善的生物降解和增强的成骨能力,从而为骨再生医学中骨形成定制的硅酸盐生物材料的制造开辟了新的温和条件方法,特别是用于有效重建具有挑战性的病理性骨缺损。